Document Detail

Zafirlukast (Accolate).
MedLine Citation:
PMID:  15010725     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Cysteinyl-leukotrienes are important mediators in the pathogenesis of asthma. Zafirlukast is a selective and competitive leukotriene receptor antagonist that has been developed for the treatment of asthma. It inhibits exercise-induced asthma, both the early- and late-phase response after allergen challenge in asthmatic subjects, and aspirin-induced asthma in aspirin-sensitive asthmatic patients. Published data indicate that zafirlukast 20 mg twice daily causes an improvement in lung function (FEV(1) and peak expiratory flow measurements) and symptom control, together with a reduction in the use of short-acting beta-agonist inhaled therapy in patients with mild to moderate asthma. Studies presented in abstract form have shown that zafirlukast 20 mg twice daily had similar efficacy as sodium cromoglycate aerosol or dry powder inhalation; in one of the studies, no advantage of the active drugs was reported over placebo. Compared to inhaled beclomethasone dipropionate therapy (200-250 microg b.i.d.), improvements in morning peak flow, FEV(1) and daytime symptom score were significantly less with zafirlukast 20 mg twice daily than with inhaled steroids. A steroid-sparing effect of zafirlukast (20 mg b.i.d.) was not observed in studies of 12-20 weeks duration in patients on inhaled steroid therapy. A significant improvement in lung function and symptom control was observed on addition of zafirlukast 80 mg twice daily in symptomatic patients maintained on high-dose inhaled steroid therapy. Meta-analysis of 5 large studies indicate that there is a significant reduction in the number of asthma exacerbations compared to placebo. Zafirlukast at 20 mg twice daily dosage appears to be well-tolerated comparable to placebo. High doses of 80 mg twice daily have been associated with reports of elevated liver enzymes. Zafirlukast is a useful addition to existing antiasthma therapies. It may be used in combination with inhaled or oral corticosteroid therapy. Further investigation of its efficacy and antiinflammatory effects will clarify its use as a first-line antiinflammatory agent in mild asthma. Zafirlukast is administered orally and may therefore be useful in patients poorly compliant with inhaled steroid therapy and with a poor inhaler technique.
K F Chung; P J Barnes
Related Documents :
2017535 - Effect of high plasma dexamethasone levels on dst sensitivity: dose-response study in d...
2340095 - In vivo evaluation of the new multiple dose powder inhaler and the rotahaler using the ...
10926345 - Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more...
22773165 - D(2)-receptor occupancy measurement of jnj-37822681, a novel fast off-rate d(2)-recepto...
11315985 - Functional and morphologic comparison of two methods to produce transient retinal ische...
15752945 - A double-blind, dose-response study of losartan in hypertensive children.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  34     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  1998 Apr 
Date Detail:
Created Date:  2004-03-10     Completed Date:  2004-05-05     Revised Date:  2006-10-26    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  375-88     Citation Subset:  -    
Copyright Information:
(c) 1998 Prous Science. All rights reserved.
Thoracic Medicine, National Heart & Lung Institute, Imperial College School of Medicine, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The idiopathic hypereosinophilic syndrome: clinical presentation, pathogenesis and therapeutic strat...
Next Document:  Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatmen...